Sarepta Therapeutics (SRPT) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
4 Jun, 2026Opening remarks and agenda
Meeting called to order at 10:00 A.M. Eastern Time, with agenda available in the webcast documents.
Attendees instructed on how to submit questions relevant to the meeting.
Board and executive committee updates
Full Board of Directors and executive committee members introduced, including CEO, CFO, and other key officers.
KPMG representatives and Computershare appointed as Inspector of Election present.
Shareholder proposals
No additional shareholder proposals were introduced as none were received per bylaws.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Sarepta Therapeutics
- Record revenue and profitability in 2024, with 68–70% growth targeted for 2025.SRPT
Q4 20249 Jul 2026 - Shipments and dosing for non-ambulatory patients suspended after two fatal liver failure cases.SRPTStatus Update9 Jul 2026
- Two-year results confirm durable efficacy, safety, and support for early intervention in DMD.SRPTStatus Update9 Jul 2026
- Q3 2024 revenue up 41%, profitability achieved, and PPMO program discontinued.SRPTQ3 20249 Jul 2026
- ELEVIDYS gene therapy provides sustained functional benefit and slows Duchenne progression by up to 73% over 3 years.SRPTStudy result8 Jul 2026
- Q2 revenues surged 51% to $360.5M, with strong ELEVIDYS and PMO product performance.SRPTQ2 20248 Jul 2026
- Strong financials and pipeline progress drive confidence in growth and regulatory stability.SRPTGoldman Sachs 47th Annual Global Healthcare Conference 20268 Jun 2026
- Q1 2026 delivered strong profitability, positive cash flow, and reaffirmed FY 2026 guidance.SRPTQ1 20267 May 2026
- Proxy seeks approval for director elections, compensation, equity plans, and auditor ratification.SRPTProxy filing24 Apr 2026